Neuronetics TMS Leadership on Display at Clinical TMS Society Annual Meeting
May 11, 2022 08:31 ET
|
Neuronetics
MALVERN, Pa., May 11, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Files Federal Lawsuit Against Brainsway for Misleading Psychiatrists and Patients
May 11, 2022 08:00 ET
|
Neuronetics
MALVERN, Pa., May 11, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
NeuroStar® Advanced Therapy for Mental Health Receives FDA Clearance for Treatment of Obsessive-Compulsive Disorder
May 10, 2022 08:31 ET
|
Neuronetics
MALVERN, Pa., May 10, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 06, 2022 16:30 ET
|
Neuronetics
MALVERN, Pa., May 06, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
NeuroStar Advanced Therapy for Mental Health Announces Partnership with Mental Health Advocate and Former Major League Baseball Player Drew Robinson
May 03, 2022 12:59 ET
|
Neuronetics
A Media Snippet accompanying this announcement is available by clicking on the image or link below: MALVERN, Pa., May 03, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial...
Neuronetics to Report First Quarter 2022 Financial and Operating Results and Host Conference Call
April 28, 2022 08:30 ET
|
Neuronetics
MALVERN, Pa., April 28, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Greenbrook and Neuronetics Announce Strengthened Commercial Partnership to Build Awareness
April 11, 2022 08:00 ET
|
Neuronetics; Greenbrook TMS
TORONTO and MALVERN, Pa., April 11, 2022 (GLOBE NEWSWIRE) -- Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy, an FDA-cleared,...
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 08, 2022 16:35 ET
|
Neuronetics
MALVERN, Pa., March 08, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
March 08, 2022 07:30 ET
|
Neuronetics
MALVERN, Pa., March 08, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients...
NeuroStar® Advanced Therapy Launches New “Tap Into a New Possibility” Campaign for Depression Awareness
March 03, 2022 10:00 ET
|
Neuronetics
MALVERN, Pa., March 03, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...